|View printer-friendly version|
|July 30, 2004 5:13 p.m.|
|Teva Calls 0.75% Convertible Debentures Due 2021 For Redemption|
Jerusalem, Israel, July 30, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Teva Pharmaceutical Finance N.V. has called for redemption on August 20, 2004 all of its outstanding 0.75% convertible senior debentures due 2021 (CUSIP Nos. 88163X AA 3, 88163X AB 1 and M87684 AA 0). The aggregate principal amount currently outstanding of these debentures is approximately $349 million.